HKD 1.66
(3.75%)
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2023 | 158.31 Million CNY | -41.15% |
2022 | 269.02 Million CNY | -43.69% |
2021 | 477.76 Million CNY | 33.33% |
2020 | 358.33 Million CNY | 1698.21% |
2019 | 19.92 Million HKD | 0.0% |
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2024 Q1 | 15.64 Million HKD | -55.52% |
2024 Q2 | 15.51 Million HKD | -0.15% |
2023 Q2 | 52.03 Million HKD | -5.52% |
2023 FY | 158.31 Million CNY | -41.15% |
2023 Q4 | 35.87 Million HKD | -30.23% |
2023 Q3 | 51.41 Million HKD | -1.19% |
2023 Q1 | 55.07 Million HKD | -16.9% |
2022 Q2 | 139.95 Million HKD | 0.0% |
2022 FY | 269.02 Million CNY | -43.69% |
2022 Q4 | 66.27 Million HKD | 2.58% |
2022 Q3 | 64.6 Million HKD | -53.84% |
2021 Q4 | 216.15 Million HKD | 0.0% |
2021 Q2 | 261.37 Million HKD | 0.0% |
2021 FY | 477.76 Million CNY | 33.33% |
2020 FY | 358.33 Million CNY | 1698.21% |
2019 FY | 19.92 Million HKD | 0.0% |
Name | Operating Expenses | Operating Expenses Difference |
---|---|---|
Uni-Bio Science Group Limited | 325.05 Million HKD | 51.296% |
CK Life Sciences Int'l., (Holdings) Inc. | 739.25 Million HKD | 78.585% |